|
1
|
Neou M, Villa C, Armignacco R, Jouinot A,
Raffin-Sanson ML, Septier A, Letourneur F, Diry S, Diedisheim M,
Izac B, et al: Pangenomic classification of pituitary
neuroendocrine tumors. Cancer Cell. 13:S15356108193052272019.
|
|
2
|
Racine MS and Barkan AL: Medical
management of growth hormone-secreting pituitary adenomas.
Pituitary. 5:67–76. 2002. View Article : Google Scholar
|
|
3
|
Molitch ME: Diagnosis and treatment of
pituitary adenomas: A Review. JAMA. 317:516–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melmed S, Popovic V, Bidlingmaier M,
Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M,
Schopohl J, Racz K, et al: Safety and efficacy of oral octreotide
in acromegaly: Results of a multicenter phase III trial. J Clin
Endocrinol Metab. 100:1699–1708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alquraini H, Del Pilar Schneider M,
Mirakhur B and Barkan A: Biochemical efficacy of long-acting
lanreotide depot/autogel in patients with acromegaly naïve to
somatostatin-receptor ligands: Analysis of three multicenter
clinical trials. Pituitary. 21:283–289. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buchfelder M, van der Lely AJ, Biller BM,
Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K,
Lavenberg J, et al: Long-Term treatment with pegvisomant:
Observations from 2090 acromegaly patients in ACROSTUDY. Eur J
Endocrinol. 179:419–427. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rouse J and Jackson SP: Interfaces between
the detection, signaling, and repair of DNA damage. Science.
297:547–551. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roussel MF: The INK4 family of cell cycle
inhibitors in cancer. Oncogene. 18:5311–5317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Melmed S: Pathogenesis of pituitary
tumors. Nat Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong W, Zhu H, Gao H, Shi W and Zhang Y,
Wang H, Li C, Song G and Zhang Y: Expression of cyclin
E/Cdk2/p27Kip1 in growth hormone adenomas. World Neurosurg.
121:e45–e53. 2019. View Article : Google Scholar
|
|
14
|
Green JL, Okerberg ES, Sejd J, Palafox M,
Monserrat L, Alemayehu S, Wu J, Sykes M, Aban A, Serra V and
Nomanbhoy T: Direct CDKN2 modulation of CDK4 alters target
engagement of CDK4 inhibitor drugs. Mol Cancer Ther. 18:771–779.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun F, Li N, Tong X, Zeng J, He S, Gai T,
Bai Y, Liu L, Lu K, Shen J, et al: Ara-C induces cell cycle G1/S
arrest by inducing upregulation of the INK4 family gene or directly
inhibiting the formation of the cell cycle-dependent complex
CDK4/cyclin D1. Cell Cycle. 18:2293–2306. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Young RJ, Waldeck K, Martin C, Foo JH,
Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, et al:
Loss of CDKN2A expression is a frequent event in primary invasive
melanoma and correlates with sensitivity to the CDK4/6 inhibitor
PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res.
27:590–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lloyd R, Osamura R, Klöppel G and Rosai J:
2017, WHO classification of tumours of the endocrine organs. 4th
edn. International Agency for Research on Cancer; Lyon:
|
|
18
|
Knosp E, Steiner E, Kitz K and Matula C:
Pituitary adenomas with invasion of the cavernous sinus space: A
magnetic resonance imaging classification compared with surgical
findings. Neurosurgery. 33:610–617. 1993.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Pabinger S, Rödiger S, Kriegner A,
Vierlinger K and Weinhäusel A: A survey of tools for the analysis
of quantitative PCR (qPCR) data. Biomol Detect Quantif. 1:23–33.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dekkers OM, Biermasz NR, Pereira M, Romijn
JA and Vandenbroucke JP: Mortality in acromegaly: A metaanalysis. J
Clin Endocrinol Metab. 93:61–67. 2008. View Article : Google Scholar
|
|
22
|
Starke RM, Raper DM, Payne SC, Vance ML,
Oldfield EH and Jane JA: Endoscopic vs microsurgical
transsphenoidal surgery for acromegaly: Outcomes in a concurrent
series of patients using modern criteria for remission. J Clin
Endocrinol Metab. 98:3190–3198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tigan AS, Bellutti F, Kollmann K, Tebb G
and Sexl V: CDK6-A review of the past and a glimpse into the
future: From cell-cycle control to transcriptional regulation.
Oncogene. 35:3083–3091. 2016. View Article : Google Scholar
|
|
24
|
Kim WY and Sharpless NE: The regulation of
INK4/ARF in cancer and aging. Cell. 127:265–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang B, Li Y, Qi G, Yuan S, Wang Z, Yu S,
Li B and He S: Clinicopathological significance of CDKN2A promoter
hyper-methylation frequency with pancreatic cancer. Sci Rep.
5:135632015. View Article : Google Scholar
|
|
26
|
Tian X, Azpurua J, Ke Z, Augereau A, Zhang
ZD, Vijg J, Gladyshev VN, Gorbunova V and Seluanov A: INK4 locus of
the tumor-resistant rodent, the naked mole rat, expresses a
functional p15/p16 hybrid isoform. Proc Natl Acad Sci USA.
112:1053–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roy S, LaFramboise WA, Liu TC, Cao D,
Luvison A, Miller C, Lyons MA, O'Sullivan RJ, Zureikat AH, Hogg ME,
et al: Loss of chromatin-remodeling proteins and/or CDKN2A
associates with metastasis of pancreatic neuroendocrine tumors and
reduced patient survival times. Gastroenterology. 154:2060–2063.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Da C, Wu K, Yue C, Bai P, Wang R, Wang G,
Zhao M, Lv Y and Hou P: N-Cadherin promotes thyroid tumorigenesis
through modulating major signaling pathways. Oncotarget.
8:8131–8142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kumar A, Gopalswamy M, Wolf A, Brockwell
DJ, Hatzfeld M and Balbach J: Phosphorylation-Induced unfolding
regulates p19INK4d during the human cell cycle. Proc Natl Acad Sci
USA. 115:3344–3349. 2018. View Article : Google Scholar
|
|
30
|
Wang Y, Jin W, Jia X, Luo R, Tan Y, Zhu X,
Yang X, Wang X and Wang K: Transcriptional repression of CDKN2D by
PML/RARα contributes to the altered proliferation and
differentiation block of acute promyelocytic leukemia cells. Cell
Death Dis. 5:e14312014. View Article : Google Scholar
|
|
31
|
Cho ES, Kang HE, Kim NH and Yook JI:
Therapeutic implications of cancer epithelial-mesenchymal
transition (EMT). Arch Pharm Res. 42:14–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tamura R, Ohara K, Morimoto Y, Kosugi K,
Oishi Y, Sato M, Yoshida K and Toda M: PITX2 expression in
non-functional pituitary neuroendocrine tumor with cavernous sinus
invasion. Endocr Pathol. 30:81–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jia W, Zhu J, Martin TA, Jiang A, Sanders
AJ and Jiang WG: Epithelial-Mesenchymal transition (EMT) markers in
human pituitary adenomas indicate a clinical course. Anticancer
Res. 35:2635–2643. 2015.PubMed/NCBI
|
|
34
|
Shapiro GI: Cyclin-Dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Finn RS, Martin M, Rugo HS, Jones S, Im
SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al:
Palbociclib and letrozole in advanced breast cancer. N Engl J Med.
375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frisone D, Charrier M, Clement S,
Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A,
Chappuis PO, McKee TA and Tsantoulis P: Durable response to
palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Cancer Biol Ther. 21:197–202. 2020. View Article : Google Scholar :
|
|
37
|
Bisi JE, Sorrentino JA, Jordan JL, Darr
DD, Roberts PJ, Tavares FX and Strum JC: Preclinical development of
G1T38: A novel, potent and selective inhibitor of cyclin dependent
kinases 4/6 for use as an oral antineoplastic in patients with
CDK4/6 sensitive tumors. Oncotarget. 8:42343–42358. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anderson E, Heller RS, Lechan RM and
Heilman CB: Regression of a nonfunctioning pituitary macroadenoma
on the CDK4/6 inhibitor palbociclib: Case report. Neurosurg Focus.
44:E92018. View Article : Google Scholar : PubMed/NCBI
|
